[Role of the individual sensitivity to various cytostatic agents in children with neuroblastomas]. 1976

T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia

Primary plasmic cultures of 33 tumors of the sympathic nervous system of children (27 neuroblastomas and 6 ganglioneuromas) were used for determination of their individual sensitivity to vincristin, vinblastin, dactinomycin, mithramycin, olivomycin, cyclophosphant bruneomycin and adriamycin. Most of the tumors were sensitive to vincristin, rubomycin an adriamycin. The data obtained in vitro and in the clinic were compared with respect to 12 cases (treatment with vincristin, combination of olivomycin with cyclophosphan, vincristin with rubomycin or cyclophosphan). Coinsidence of the results was observed in 8 cases. The method of primary plasmic cultures may be successfully used for determination of individual sensitivity of children with neuroblastomas to various cytostatics.

UI MeSH Term Description Entries
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005729 Ganglioneuroma A benign neoplasm that usually arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. The tumor may present clinically with HORNER SYNDROME or diarrhea due to ectopic production of vasoactive intestinal peptide. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p966) Gangliocytoma,Gangliocytomas,Ganglioneuromas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
January 1995, Klinicheskaia laboratornaia diagnostika,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
August 2017, Current opinion in allergy and clinical immunology,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
May 1976, Minerva pediatrica,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
January 1968, Acta histochemica,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
January 2004, Otolaryngologia polska = The Polish otolaryngology,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
December 1981, Nederlands tijdschrift voor geneeskunde,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
June 1988, Biulleten' eksperimental'noi biologii i meditsiny,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
January 1977, Cytobios,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
January 1970, Pediatriia,
T G Terent'eva, and A F Bukhny, and L A Drunov, and M A Izrail'skaia
January 1984, Investigational new drugs,
Copied contents to your clipboard!